TRACON Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
TRACON Pharmaceuticals (TCON) announced that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Jefferies Virtual Healthcare Conference on June 4th at 4:00 pm EDT. The company, focused on developing targeted cancer therapeutics, aims to start a registrational trial for envafolimab in the U.S. in the second half of 2020. TRACON's pipeline includes TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. Live webcast access is available on the company’s website.
- None.
- None.
SAN DIEGO, June 01, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 Jefferies Virtual Healthcare Conference on Thursday, June 4th, at 4:00 pm EDT.
To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient product development platform. The Company’s clinical-stage pipeline includes: envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of starting a registrational trial in the U.S. in the second half of 2020; TRC253, a small molecule drug candidate being developed of the treatment of prostate cancer; TRC102, a small molecule drug candidate being developed for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
| Company Contact: | Investor Contact: |
| Mark Wiggins | Andrew McDonald |
| Chief Business Officer | LifeSci Advisors LLC |
| (858) 251-3492 | 646-597-6987 |
| mwiggins@traconpharma.com | Andrew@lifesciadvisors.com |
FAQ
What is TRACON Pharmaceuticals presenting at the 2020 Jefferies Virtual Healthcare Conference?
When will TRACON start its registrational trial for envafolimab?
What cancer therapies are in TRACON's pipeline?
How can I access the live webcast of TRACON's presentation?
